首页> 外文期刊>Nature >Deterministic direct reprogramming of somatic cells to pluripotency
【24h】

Deterministic direct reprogramming of somatic cells to pluripotency

机译:确定性直接将体细胞重编程为多能性

获取原文
获取原文并翻译 | 示例
       

摘要

Somatic cells can be inefficiently and stochastically reprogrammed into induced pluripotent stem (iPS) cells by exogenous expression of Oct4 (also called Pou5fl), Sox2, Klf4 and Myc (hereafter referred to as OSKM). The nature of the predominant rate-limiting barrier(s) preventing the majority of cells to successfully and synchronously reprogram remains to be defined. Here we show that depleting Mbd3, a core member of the Mbd3/NuRD (nucleosome remodelling and deacetylation) repressor complex, together with OSKM transduction and reprogramming in naive pluripotency promoting conditions, result in deterministic and synchronized iPS cell reprogramming (near 100% efficiency within seven days from mouse and human cells). Our findings uncover a dichotomous molecular function for the reprogramming factors, serving to reactivate endogenous pluripotency networks while simultaneously directly recruiting the Mbd3/NuRD repressor complex that potently restrains the reactivation of OSKM downstream target genes. Subsequently, the latter interactions, which are largely depleted during early pre-implantation development in vivo, lead to a stochastic and protracted reprogramming for the dissection of molecular dynamics leading to establishing pluripotency at unprecedented flexibility and resolution.
机译:通过外源表达Oct4(也称为Pou5f1),Sox2,Klf4和Myc(以下称为OSKM),可以将体细胞低效率地和随机地重编程为诱导性多能干(iPS)细胞。阻止大多数细胞成功且同步地重新编程的主要限速屏障的性质仍有待确定。在这里,我们显示耗尽Mbd3(Mbd3 / NuRD(核小体重塑和去乙酰化)阻遏物复合体的核心成员)以及OSKM转导和在幼稚多能性促进条件下进行重编程会导致确定性和同步的iPS细胞重编程(在100%的效率下,距老鼠和人类细胞7天)。我们的发现揭示了重编程因子的二分分子功能,可用于重新激活内源多能性网络,同时直接募集有效抑制OSKM下游靶基因重新激活的Mbd3 / NuRD阻遏物复合物。随后,后者的相互作用在体内早期植入前的早期发育过程中被大量消耗,导致对分子动力学的解剖学进行了随机且旷日持久的重编程,从而以前所未有的灵活性和分辨率建立了多能性。

著录项

  • 来源
    《Nature》 |2013年第7469期|65-70|共6页
  • 作者单位

    The Department of Molecular Genetics, Weizmann Institute of Science, Rehovot 76100, Israel;

    The Department of Molecular Genetics, Weizmann Institute of Science, Rehovot 76100, Israel;

    The Department of Molecular Genetics, Weizmann Institute of Science, Rehovot 76100, Israel;

    The Department of Molecular Genetics, Weizmann Institute of Science, Rehovot 76100, Israel;

    The Department of Molecular Genetics, Weizmann Institute of Science, Rehovot 76100, Israel;

    The Department of Molecular Genetics, Weizmann Institute of Science, Rehovot 76100, Israel;

    The Department of Molecular Genetics, Weizmann Institute of Science, Rehovot 76100, Israel;

    The Department of Molecular Genetics, Weizmann Institute of Science, Rehovot 76100, Israel;

    The Department of Molecular Genetics, Weizmann Institute of Science, Rehovot 76100, Israel;

    The Department of Molecular Genetics, Weizmann Institute of Science, Rehovot 76100, Israel;

    The Department of Molecular Genetics, Weizmann Institute of Science, Rehovot 76100, Israel;

    The Department of Molecular Genetics, Weizmann Institute of Science, Rehovot 76100, Israel;

    The Department of Molecular Genetics, Weizmann Institute of Science, Rehovot 76100, Israel;

    The Department of Molecular Genetics, Weizmann Institute of Science, Rehovot 76100, Israel;

    The Department of Immunology, Weizmann Institute of Science, Rehovot 76100, Israel;

    The Department of Immunology, Weizmann Institute of Science, Rehovot 76100, Israel;

    The Department of Immunology, Weizmann Institute of Science, Rehovot 76100, Israel;

    The Department of Biological Regulation, Weizmann Institute of Science, Rehovot 76100, Israel,The Department of Computer Science, Weizmann Institute of Science, Rehovot 76100, Israel;

    The Department of Biological Regulation, Weizmann Institute of Science, Rehovot 76100, Israel,The Department of Computer Science, Weizmann Institute of Science, Rehovot 76100, Israel;

    The Department of Structural Biology, Weizmann Institute of Science, Rehovot 76100, Israel;

    The Israel National Center for Personalized Medicine, Weizmann Institute of Science, Rehovot 76100, Israel;

    The Israel National Center for Personalized Medicine, Weizmann Institute of Science, Rehovot 76100, Israel;

    The Department of Biological Regulation, Weizmann Institute of Science, Rehovot 76100, Israel,The Department of Computer Science, Weizmann Institute of Science, Rehovot 76100, Israel;

    The Department of Immunology, Weizmann Institute of Science, Rehovot 76100, Israel;

    The Department of Molecular Genetics, Weizmann Institute of Science, Rehovot 76100, Israel;

    The Department of Molecular Genetics, Weizmann Institute of Science, Rehovot 76100, Israel;

  • 收录信息 美国《科学引文索引》(SCI);美国《工程索引》(EI);美国《生物学医学文摘》(MEDLINE);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

  • 入库时间 2022-08-18 02:53:47

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号